In recent years, the introduction of targeted therapies has led to a revolutionary change in the management of a number of different types of blood cancer. In particular, B-cell malignancies, such as CLL, SLL and WM have been shown to be effectively treated with targeted agents. Zanubrutinib, a novel Bruton’s tyrosine kinase (BTK) inhibitor, has recently been introduced to the market for the treatment of these diseases. Zanubrutinib is an option for patients with B-cell malignancies as it has been evaluated in clinical studies for disease management in certain B-cell malignancies.
As targeted cancer therapies continue to emerge, many are as effective as chemotherapy but more precise in their action. Zanubrutinib is a targeted therapy for certain blood cancers. It is expected that patients will remain on treatment for a long period of time and it is during this time that monitoring for any adverse effects of zanubrutinib occurs. In addition to detecting any side effects early, monitoring helps to evaluate the effectiveness of zanubrutinib, assess the impact of zanubrutinib on blood counts and also review liver and kidney function. The monitoring process also helps to evaluate patient adherence to zanubrutinib and to identify potential drug interactions.
Understanding the processes involved in follow-up visits can support better comprehension of treatment and help build confidence throughout the treatment course.
Why Monitoring Is Important During Zanubrutinib Use
Everyone responds differently to zanubrutinib even though it is a targeted therapy. There are many variables that affect how a patient will react to treatment, including the patient’s age, other medical problems, the stage of the patient’s cancer and prior treatments for cancer.
Rather than simply prescribing the medication and waiting for results, physicians carefully evaluate patients throughout therapy. Regular follow-up allows them to identify problems before they become serious and make adjustments whenever necessary.
The primary goals of monitoring include:
- Evaluating treatment effectiveness
- Detecting side effects early
- Monitoring blood counts
- Assessing liver and kidney function
- Reviewing medication adherence
- Identifying possible drug interactions
- Supporting long-term disease control
Monitoring may support safety assessments and disease management.
Initial Assessment Before Starting Treatment
A patient must first undergo an initial assessment of overall health before he or she can begin using zanubrutinib. This assessment will serve as a basis for comparison for future monitoring. The assessment will reveal the overall health of a patient and indicate whether or not the patient may need close monitoring due to pre-existing medical conditions.
A physician’s initial assessment of a patient with chronic lymphocytic leukaemia (CLL) before starting treatment with zanubrutinib typically involves a comprehensive medical history, current medications, previous cancer treatment(s) and any other medical conditions the patient may have. The patient will also receive a physical examination to check for signs of disease, such as enlarged lymph nodes or spleen, and for any signs of illness or weakness.
Initial investigations commonly include:
- Complete blood count (CBC)
- Liver function tests
- Kidney function tests
- Assessment of cardiovascular history
- Infection history
- Review of current medications
- Disease-specific laboratory investigations
- Imaging studies when clinically appropriate
With this information, healthcare professionals can monitor any changes to patient’s health after the treatment starts.
Follow-Up During the Early Phase of Treatment
The first few months of therapy are usually seen as a time when patients are settling into treatment and the physician is assessing early response to treatment. The initial period of treatment is usually followed by more frequent reviews, often held every few months.
Review of the patient’s general condition and assessment of any new symptoms or side effects of the prescribed medications. Repeat blood tests in order to check changes in the blood counts and to monitor the effects of the treatment.
Patients are often asked about:
- Fatigue levels
- Appetite
- Daily activities
- New symptoms
- Medication schedule
- Missed doses
- Signs of infection
Early follow-up visits help to identify problems and allow intervention by the physician and support staff.
Laboratory Monitoring Throughout Treatment
While on therapy for zanubrutinib, blood tests will be taken on a regular basis to determine the extent to which both the disease and the rest of the body are being affected by the treatment. The frequency of blood tests will vary from patient to patient, however.
Common laboratory tests include:
- Complete blood count (CBC)
- White blood cell count
- Hemoglobin level
- Platelet count
- Liver function tests
- Kidney function tests
- Electrolyte levels when indicated
- Disease-specific laboratory markers
Lab results are used by the patient’s doctor to decide whether to continue or modify treatment.
Monitoring Treatment Response
Treating leukemia is more than giving medications. After starting treatment, the physician monitors whether the disease is responding to the treatment or not. This monitoring is done by combining the laboratory findings with the clinical evaluation of the patient.
These changes happen slowly over time and as such are evaluated by the treating physician at individual appointments over time.
Healthcare providers commonly assess:
- Reduction in enlarged lymph nodes
- Improvement in blood counts
- Decrease in leukemia-related symptoms
- Improvement in fatigue
- Reduction in spleen enlargement
- Overall physical well-being
In some cases, additional imaging or other specialized testing may be needed to evaluate treatment response.
Monitoring for Side Effects
While many patients find zanubrutinib to be well-tolerated, there are side effects that can occur. Early detection and management by the healthcare team is important in making sure any side effects do not become too severe.
Persistent or worsening side effects during zanubrutinib treatment should be reported to the healthcare team. Ongoing communication supports patient safety during treatment.
Symptoms that should be reported include:
- Fever
- Persistent cough
- Unusual bruising
- Bleeding
- Shortness of breath
- Chest discomfort
- Severe fatigue
- Persistent diarrhea
- New skin changes
Supportive medications, temporary treatment interruption when clinically indicated, and additional evaluation or management may be considered based on individual patient needs.
Infection Prevention During Zanubrutinib Use
As targeted therapies can affect immune function, even patients with well controlled disease are at increased risk of certain types of infections.
In follow-up health care visits, patients are typically counseled by their health care providers regarding infection prevention strategies while on zanubrutinib. Patients are strongly urged to seek medical attention immediately should they experience any symptoms of infection.
Important preventive measures include:
- Practicing good hand hygiene
- Reporting fever immediately
- Avoiding close contact with individuals who are ill
- Following recommended vaccination schedules
- Attending scheduled medical appointments
Infectious disease prevention is important for the long-term management of the patient in order to avoid possible complications from the disease itself or from the treatment of the disease.
Reviewing Other Medications
At each follow-up visit, a comprehensive review of all current and recent medications is conducted. This includes prescription drugs, over-the-counter products, vitamins, and herbal supplements. Even previously discontinued medications may present interaction risks with zanubrutinib. Any newly initiated medications, including those prescribed by other healthcare providers, should be communicated to the treating healthcare team.
This review helps to prevent unwanted drug interactions.
Importance of Medication Adherence
Missing a dose of zanubrutinib or stopping it for any reason without first speaking with a doctor could reduce its effectiveness.
Factors may interfere with adherence to the prescribed medication regimen. Healthcare providers typically assess potential barriers to consistent zanubrutinib use and implement strategies to address them.
Patients can improve adherence by:
- Taking medication at the same time each day
- Using reminder alarms
- Keeping a medication diary
- Refilling prescriptions before they run out
- Discussing with the doctor about any side effects as soon as they occur instead of the patient stopping the treatment on his/her own.
Consistent adherence to the prescribed medication regimen supports optimal therapeutic outcomes.
Long-Term Follow-Up
Although for the patient who is clinically stable the follow-up appointments may be less frequent, monitoring of the patient throughout the treatment period is essential.
Monitoring of long-term disease effects, treatment-related outcomes, delayed complications, and disease progression is essential, alongside ongoing evaluation of patient safety and overall quality of life.
Long-term evaluations commonly include:
- Assessment of disease progression
- Monitoring long-term safety
- Laboratory testing
- Review of treatment goals
- Management of ongoing side effects
- Evaluation of overall health
Individual responses to treatment may vary. Continued participation in long-term follow-up appointments can support ongoing assessment of treatment effectiveness and allow for adjustments when clinically indicated.
Building a Strong Partnership with the Healthcare Team
Ongoing communication with the healthcare team is critical for successful zanubrutinib use. Patients should feel comfortable to inform their healthcare team about any concerns, no matter how trivial they may seem.
Keeping the healthcare team informed is crucial to making the best treatment decisions with the most current and most accurate information.
Patients should report:
- New symptoms
- Missed doses
- Medication changes
- Hospital admissions
- Lifestyle changes
- Concerns about treatment
An open relationship between the patient and healthcare team will help ensure the safest treatment and best long-term outcome.
Conclusion
Monitoring long-term safety of patients with zanubrutinib is key to successful treatment. Although targeted therapies have changed the landscape of the treatment of most B-cell malignancies, long-term monitoring of patients on targeted therapies is necessary and ensures that the best possible treatment is given and remains safe.
By conducting routine laboratory tests, performing physical exams, reviewing patients’ medications, and monitoring how patients are responding to treatment, patients can be made aware of any potential problems early on and their healthcare provider can make informed treatment decisions. Patients are also expected to attend their scheduled appointments, take their prescribed medication, and report any new symptoms to their healthcare provider.
Ongoing monitoring within the framework of a structured monitoring protocol remains crucial in the long term for the treatment of B-cell malignancies with targeted therapies like zanubrutinib. The monitoring concept supports individualized treatment that is of high quality and ensures the best long-term treatment outcome for patients.
